PPTA's 2012 Plasma Protein Forum

Over 300 patients, policymakers and industry representatives convened in Washington, DC on June 21-22 for the 2012 Plasma Protein Forum. The conference centered on the theme of rare diseases.

Highlights of the 2012 Forum:

Myrl Weinberg, President of the National Health Council delivered a dynamic keynote assessing risk and benefit from a patient perspective.

	The Honorable Michael C. Burgess, (R-TX), outlined health policy perspectives from the U.S. Congress. Other presentations and panels addressed the impact of the Affordable Health Care Act on the States, the cost effectiveness of plasma protein therapies.

PPTA staff welcomes attendees to the Forum	Kym Kilbourne, Congressman Michael Burgess and Jan M. Bult

Josh Penrod presents Rudolf Meixner, President, Europlasma GmbH with IQPP certification -- the first in the Czech Republic	Ileana Carlisle delivers a testament to industry in final act as Source Board Chair

Exhibitors demonstrate the latest industry innovations	Attendees enjoy informal opportunities to connect

Steve Pettaway received the Otto Schwarz Award for leadership in the industry and scientific fields of expertise	Otto Schwarz Award accepted by Christopher Healey, Grifols

Created on June 22 2012.

Media and Information

PPTA News

Public Review until April 21: Proposed Confirmation of Two IQPP Standards +
The following proposed actions are hereby opened for public review:
- Confirmation (continued implementation) of Version 3.0 of the IQPP Cross Donation Management Standard
- Confirmation (continued implementation) of Version 1.0 of the IQPP Donor Fluid Administration Standard
Read More
PPTA encourages EDQM to take a patient-centric approach in the implementation of its Plasma Supply Management Recommendations +

The European Commission and the European Directorate for the Quality of Medicines (EDQM) recently published recommendations on plasma supply management in Europe. The recommendations were drafted by a working group of transfusion specialists representing national blood services (also called the TS093 working group). PPTA thanks the EDQM and the European Commission for addressing this important issue but is concerned that the recommendations do not go far enough towards ensuring the collection of sufficient plasma to meet the growing clinical need for plasma-derived medicinal products (PDMPs).
Read More
New Coronavirus (SARS-CoV-2) and Plasma Protein Therapies (updated February 17, 2020) +

Recent international reports have highlighted the emergence of a new coronavirus in Wuhan, Hubei Province, China (1). The 2019 Novel Coronavirus (2019-noCoV), now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified by Chinese authorities in December 2019 and since then has been associated with pneumonia in over 70,000 persons in China and more than 1,700 deaths (1-3). *
Read More

1
2
3

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Media and Information

Advocacy

Copyright © 2020 PPTA. All rights reserved. (202) 789-3100

Terms of Use | Privacy Statement | Sitemap